Corcept Therapeutics Incorporated (CORT)

Q: What's priced into Corcept Therapeutics Incorporated (CORT) stock?

CORT is expensive versus peers, with a valuation premium of 5.02 points and a recent increase in its valuation score. The snapshot describes that valuation as justified by growth optionality, but model confidence is low, so expectations around future growth and product potential remain uncertain.

Q: What does the Corcept Therapeutics Incorporated (CORT) outlook hinge on?

The multi-year view depends on CORT sustaining growth and delivering on its raised guidance without reversing course, which could damage credibility. Regulatory progress for relacorilant and continued demand for Lifyorli are key company-specific swing factors. A weakening jobs trend could weigh on healthcare names, while continued strong results from sector peers could support sector momentum.

NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-23

$85.86-20.13%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Corcept Therapeutics Incorporated’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	373.8M
EPS	—	1.13
FY 2026 · Annual
Revenue	$1.1B–$1.2B	1.11B
EPS	—	2.036
FY 2027 · Annual
Revenue	—	1.59B
EPS	—	4.292

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Lifyorli plus nab-paclitaxel reduces death risk by 35%	New cancer drug Lifyorli cuts death risk by 35%.	Intact	New data shows less than 20% death risk reduction	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Lifyorli launched in 2026-Q1 with FDA approval and generated $47.6 million revenue in 2026-Q2. Over 1,300 patients started treatment by 2026-Q2 with accelerating demand. The trajectory shows delivering initial commercial success and advancing clinical trials. Delivery assessment Oct 24, 2026
Advance relacorilant NDA for Cushing's syndrome approval	A supporting condition in Corcept Therapeutics Incorporated's published investment case. The stated target is NDA approval expected by end of 2026.	Intact	NDA approval delayed beyond 2026 or rejected	NDA approval expected by end of 2026; no delay reported FDA approval reported; Q2 2026 revenue guidance raised to $950-$1,050M; stock jumped 17.4%. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management resubmitted the NDA in June 2026 with a PDUFA date of December 17, 2026. The company remains engaged with FDA and confident in approval. The trajectory is consistent with ongoing regulatory progress. Delivery assessment Oct 24, 2026
2026 revenue reaches $950-$1,050 million	A primary condition in Corcept Therapeutics Incorporated's published investment case. The stated target is >= $950 million and <= $1,050 million.	Intact	Revenue falls below $950 million in FY26	Revenue: $256.147M FY2026-Q2; GAAP. Published target: >= $950 million and <= $1,050 million. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026256,147,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: a77b10bc-0bb7-4827-9118-4cf3a8bd9b6e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	3 / 4
2026-07-30	Unavailable	$1,487,066,170	3 / 5
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$1,527,353,570	3 / 5
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	$1,527,353,570	3 / 5
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-11	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 3
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 3
2026-09-10	Unavailable	Unavailable	4 / 3
2026-09-11	Unavailable	Unavailable	4 / 3
2026-09-12	Unavailable	Unavailable	4 / 3
2026-09-13	Unavailable	Unavailable	4 / 3
2026-09-14	Unavailable	Unavailable	4 / 3
2026-09-15	Unavailable	Unavailable	4 / 3
2026-09-16	Unavailable	Unavailable	4 / 3
2026-09-17	Unavailable	Unavailable	4 / 3
2026-09-18	Unavailable	Unavailable	4 / 3
2026-09-19	Unavailable	Unavailable	4 / 3
2026-09-20	Unavailable	Unavailable	4 / 3
2026-09-21	Unavailable	Unavailable	4 / 3
2026-09-22	Unavailable	Unavailable	4 / 3
2026-09-23	Unavailable	Unavailable	4 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 3
2026-09-27	Unavailable	Unavailable	4 / 3
2026-09-28	Unavailable	Unavailable	4 / 3
2026-09-29	Unavailable	Unavailable	4 / 3
2026-09-30	Unavailable	Unavailable	4 / 3
2026-10-01	Unavailable	Unavailable	4 / 3
2026-10-02	Unavailable	Unavailable	4 / 3
2026-10-03	Unavailable	Unavailable	4 / 3
2026-10-04	Unavailable	Unavailable	4 / 3
2026-10-05	Unavailable	Unavailable	4 / 3
2026-10-06	Unavailable	Unavailable	4 / 3
2026-10-07	Unavailable	Unavailable	4 / 3
2026-10-08	Unavailable	Unavailable	4 / 3
2026-10-09	Unavailable	Unavailable	4 / 3
2026-10-10	Unavailable	Unavailable	4 / 3
2026-10-11	Unavailable	Unavailable	4 / 3
2026-10-12	Unavailable	Unavailable	4 / 3
2026-10-13	Unavailable	Unavailable	4 / 3
2026-10-14	Unavailable	Unavailable	4 / 3
2026-10-15	Unavailable	Unavailable	4 / 3
2026-10-16	Unavailable	Unavailable	4 / 3
2026-10-17	Unavailable	Unavailable	4 / 3
2026-10-18	Unavailable	Unavailable	4 / 3
2026-10-19	Unavailable	Unavailable	4 / 3
2026-10-20	Unavailable	Unavailable	4 / 3
2026-10-21	Unavailable	Unavailable	4 / 3
2026-10-22	Unavailable	Unavailable	4 / 3
2026-10-23	Unavailable	Unavailable	4 / 3
2026-10-24	Unavailable	Unavailable	4 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	2	0
2026-06-01	5	1	0
2026-07-01	5	1	1
2026-08-01	4	0	1
2026-09-01	4	0	1
2026-10-01	4	0	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Lifyorli plus nab-paclitaxel reduces death risk by 35%Direct metric needs a verified mapping
2026 revenue reaches $950-$1,050 millionRevenue: $256.147M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-63.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Corcept Therapeutics Incorporated outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CORT is a high-growth biopharmaceutical business with commercial and regulatory execution risks. Its long-term thesis is intact, supported by strong recent results and rising guidance, but earnings quality is fragile and overall risk is elevated.

What's priced into Corcept Therapeutics Incorporated

CORT is expensive versus peers, with a valuation premium of 5.02 points and a recent increase in its valuation score. The snapshot describes that valuation as justified by growth optionality, but model confidence is low, so expectations around future growth and product potential remain uncertain.

What the fundamentals likely do

Near term, revenue growth has been strong: quarterly revenue rose from $164.9 million to $256.1 million, and management raised 2026 revenue guidance to $1.1-$1.2 billion. Lifyorli’s launch is showing early demand, while relacorilant’s Cushing’s syndrome application is progressing toward a December 17, 2026 FDA decision. Near-term execution risk remains meaningful because recent earnings misses are noted, despite a July earnings beat, and a CEO transition and filed litigation add uncertainty.

What Corcept Therapeutics Incorporated hinges on

The multi-year view depends on CORT sustaining growth and delivering on its raised guidance without reversing course, which could damage credibility. Regulatory progress for relacorilant and continued demand for Lifyorli are key company-specific swing factors. A weakening jobs trend could weigh on healthcare names, while continued strong results from sector peers could support sector momentum.

Bottom line

Over the next 1-3 years, CORT’s thesis rests on turning strong revenue growth and early product demand into durable execution while managing regulatory and leadership uncertainty. The business setup is promising, but its expensive valuation and fragile earnings quality leave little room for execution setbacks. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	373.8M
EPS	—	1.13
FY 2026 · Annual
Revenue	$1.1B–$1.2B	1.11B
EPS	—	2.036
FY 2027 · Annual
Revenue	—	1.59B
EPS	—	4.292

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	3 / 4
2026-07-30	Unavailable	$1,487,066,170	3 / 5
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$1,527,353,570	3 / 5
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	$1,527,353,570	3 / 5
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-11	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 3
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 3
2026-09-10	Unavailable	Unavailable	4 / 3
2026-09-11	Unavailable	Unavailable	4 / 3
2026-09-12	Unavailable	Unavailable	4 / 3
2026-09-13	Unavailable	Unavailable	4 / 3
2026-09-14	Unavailable	Unavailable	4 / 3
2026-09-15	Unavailable	Unavailable	4 / 3
2026-09-16	Unavailable	Unavailable	4 / 3
2026-09-17	Unavailable	Unavailable	4 / 3
2026-09-18	Unavailable	Unavailable	4 / 3
2026-09-19	Unavailable	Unavailable	4 / 3
2026-09-20	Unavailable	Unavailable	4 / 3
2026-09-21	Unavailable	Unavailable	4 / 3
2026-09-22	Unavailable	Unavailable	4 / 3
2026-09-23	Unavailable	Unavailable	4 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 3
2026-09-27	Unavailable	Unavailable	4 / 3
2026-09-28	Unavailable	Unavailable	4 / 3
2026-09-29	Unavailable	Unavailable	4 / 3
2026-09-30	Unavailable	Unavailable	4 / 3
2026-10-01	Unavailable	Unavailable	4 / 3
2026-10-02	Unavailable	Unavailable	4 / 3
2026-10-03	Unavailable	Unavailable	4 / 3
2026-10-04	Unavailable	Unavailable	4 / 3
2026-10-05	Unavailable	Unavailable	4 / 3
2026-10-06	Unavailable	Unavailable	4 / 3
2026-10-07	Unavailable	Unavailable	4 / 3
2026-10-08	Unavailable	Unavailable	4 / 3
2026-10-09	Unavailable	Unavailable	4 / 3
2026-10-10	Unavailable	Unavailable	4 / 3
2026-10-11	Unavailable	Unavailable	4 / 3
2026-10-12	Unavailable	Unavailable	4 / 3
2026-10-13	Unavailable	Unavailable	4 / 3
2026-10-14	Unavailable	Unavailable	4 / 3
2026-10-15	Unavailable	Unavailable	4 / 3
2026-10-16	Unavailable	Unavailable	4 / 3
2026-10-17	Unavailable	Unavailable	4 / 3
2026-10-18	Unavailable	Unavailable	4 / 3
2026-10-19	Unavailable	Unavailable	4 / 3
2026-10-20	Unavailable	Unavailable	4 / 3
2026-10-21	Unavailable	Unavailable	4 / 3
2026-10-22	Unavailable	Unavailable	4 / 3
2026-10-23	Unavailable	Unavailable	4 / 3
2026-10-24	Unavailable	Unavailable	4 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings